Online citations, reference lists, and bibliographies.
← Back to Search

Emerging Drugs For Immune Thrombocytopenia (ITP)

A. Salama
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
ABSTRACT Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody production against platelets, increased platelet destruction, and, in some cases, impaired thrombopoiesis. The majority of affected patients have significant bleeding risks due to low platelet counts and require treatment. The etiology of ITP is an immunological labyrinth. Currently available treatment options are usually not only nonspecific, but are also associated with some risks. Areas covered: Several useful drugs for the treatment of ITP are currently available. Furthermore, ongoing trials with new drugs and preclinical development of additional drugs may help to improve and determine their value. Expert opinion: ITP is a heterogeneous complex requiring individualized treatment. None of the available drugs are specific, nor are they invariably safe and effective. Thus, the need for specific therapy is evident.
This paper references
10.1111/j.1365-2141.1983.tb01234.x
Deposition of the terminal C5b‐9 complement complex on erythrocytes by human red cell autoantibodies
A. Salama (1983)
10.1201/9781498713016-16
Immune thrombocytopenia.
R. McMillan (1983)
Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody.
S. Clarkson (1986)
10.1056/NEJM198605083141907
Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody
S. Clarkson (1986)
10.1016/S0887-7963(92)70152-7
Use of Rh antibodies in the treatment of autoimmune thrombocytopenia.
A. Salama (1992)
Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature.
C. Schiavotto (1993)
10.1016/s0887-7963(97)80114-9
Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients.
A. Scaradavou (1997)
Immune thrombocytopenic purpura in pregnancy.
G. Christiaens (1998)
Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy.
K. Simpson (1998)
A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura.
G. Newman (2001)
Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
J. Davis (2001)
10.1182/BLOOD.V97.9.2549
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.
J. Portielje (2001)
10.1046/j.1365-2141.2001.02627.x
A dose of 75 μg/kg/d of i.v. anti‐D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura
G. Newman (2001)
10.1182/BLOOD.V99.6.1922
Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?
N. Cooper (2002)
10.1007/springerreference_38690
Immune thrombocytopenic purpura.
I. Khouri (2002)
10.1002/ART.10681
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
K. Kalunian (2002)
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with antiCD154: a randomized, double-blind, placebo-controlled trial
KC Kalunian (2002)
10.1002/AJH.10424
Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti‐D with routine care
J. George (2003)
10.1046/j.1365-2567.2003.01617.x
Targeting dendritic cells with CD44 monoclonal antibodies selectively inhibits the proliferation of naive CD4+ T‐helper cells by induction of FAS‐independent T‐cell apoptosis
C. Termeer (2003)
Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine.
F. Rodeghiero (2003)
10.1084/jem.20040139
In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes
Q. Tang (2004)
10.1016/J.IT.2004.07.003
Platelets: signaling cells in the immune continuum.
A. Weyrich (2004)
10.1111/J.1600-0609.2004.00244.X
Efficacy and safety of anti‐D given by subcutaneous injection to patients with autoimmune thrombocytopenia
O. Meyer (2004)
10.1182/BLOOD-2003-06-2167
Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura.
M. Kuwana (2004)
10.1160/TH03-10-0650
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.
J. Bussel (2004)
10.1016/J.JPEDS.2005.11.019
Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
M. Tarantino (2006)
Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura.
P. Fogarty (2006)
10.4049/jimmunol.177.3.1451
Suppression of Disease in New Zealand Black/New Zealand White Lupus-Prone Mice by Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells1
K. Scalapino (2006)
10.1126/SCIENCE.1129594
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Y. Kaneko (2006)
10.1111/j.1538-7836.2006.02147.x
Prevalence of immune thrombocytopenia: analyses of administrative data
J. Segal (2006)
10.1016/J.BBRC.2006.01.030
Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.
T. Raju (2006)
10.1111/j.1423-0410.2006.00839.x
A novel antigen‐specific capture assay for the detection of platelet antibodies and HPA‐1a phenotyping
O. Meyer (2006)
10.1097/MOH.0b013e3282ab98c7
The epidemiology of immune thrombocytopenic purpura
P. Fogarty (2007)
10.1111/j.1365-2141.2006.06431.x
High‐level serum B‐cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura
F. Emmerich (2007)
10.1111/j.1538-7836.2007.02804.x
Modulation of immune response with cytotoxic T‐lymphocyte‐associated antigen 4 immunoglobulin‐induced anergic T cells in chronic idiopathic thrombocytopenic purpura 2
X. Zhang (2007)
10.1053/J.SEMINHEMATOL.2007.04.005
Cytokines for the treatment of thrombocytopenia.
S. Ciurea (2007)
10.7326/0003-4819-146-1-200701020-00006
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
D. Arnold (2007)
10.1097/MOH.0b013e3282b9748f
Immune thrombocytopenic purpura in adults
B. Godeau (2007)
10.1002/pbc.20830
A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
Sarah H. O'Brien (2007)
10.1111/j.1600-0609.2007.00998.x
Epidemiology and pathophysiology of immune thrombocytopenic purpura
T. Gernsheimer (2008)
10.1002/AJH.21109
Is splenectomy still the gold standard for the treatment of chronic ITP?
F. Rodeghiero (2008)
10.1111/j.1365-2141.2008.07039.x
The effect of anti‐CD40 ligand in immune thrombocytopenic purpura
Vivek L. Patel (2008)
10.1185/03007990802377461
Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey
C. Snyder (2008)
Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura.
X. Zhang (2008)
10.1002/AJH.20992
Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpura
R. McMillan (2008)
Health-related quality of life of immune thrombocytopenic purpura patients: results from a webbased survey
CF Snyder (2008)
10.1182/blood-2008-07-166439
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.
A. Podolanczuk (2009)
10.1002/ajh.21500
Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura
M. Danese (2009)
10.1007/s00277-009-0848-x
Subcutaneous anti-d globulin application is a safe treatment option of immune thrombocytopenia in children
M. Trebo (2009)
10.1185/03007990903362388
Analysis of the impact and burden of illness of adult chronic ITP in the US
M. Saleh (2009)
10.1182/blood-2008-07-168146
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
D. Goldenberg (2009)
10.1111/j.1537-2995.2008.02083.x
Investigation of whether the acute hemolysis associated with Rho(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model
Ann Reed Gaines (2009)
10.1182/blood-2009-01-129155
The ITP syndrome: pathogenic and clinical diversity.
D. Cines (2009)
10.1002/pbc.22248
Subcutaneous anti‐D treatment of idiopathic thrombocytopenic purpura in children
M. Kjaersgaard (2009)
Properties and structurefunction relationships of veltuzumab (hA20), a humanized antiCD20 monoclonal antibody
DM Goldenberg (2009)
10.1053/j.seminhematol.2010.01.007
CD20-targeted therapy: the next generation of antibodies.
T. van Meerten (2010)
10.1185/03007990903451298
Impact of ITP on physician visits and workplace productivity
M. Tarantino (2010)
10.1053/j.seminhematol.2010.03.002
Toxicities of the thrombopoietic growth factors.
A. Cuker (2010)
10.1182/blood-2009-06-225565
International consensus report on the investigation and management of primary immune thrombocytopenia.
D. Provan (2010)
10.1200/JCO.2010.27.9836
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
B. Cheson (2010)
10.1002/ajh.21833
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic‐uremic syndromes
Deirdra R. Terrell (2010)
10.1007/s00277-010-1087-x
Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis
M. Khellaf (2010)
10.1182/blood-2009-07-229815
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
F. Zaja (2010)
10.1002/ajh.21616
The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports
D. Terrell (2010)
Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94033/2007 rev.2)
(2010)
Immune thrombocytopenia. Hematology
A Cuker (2010)
10.1182/blood-2011-08-371138
A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
A. Cuker (2011)
10.1182/blood-2010-08-302984
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.
C. Neunert (2011)
10.4049/jimmunol.1003780
Neonatal Fc Receptor Blockade by Fc Engineering Ameliorates Arthritis in a Murine Model
Dipesh A. Patel (2011)
10.1136/ard.2010.133256
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma
Karen Fröhlich (2011)
10.1007/s12185-011-0791-1
Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review
Y. Kurata (2011)
10.1586/ehm.10.76
Current treatment options for primary immune thrombocytopenia
A. Salama (2011)
10.1182/blood-2010-05-280115
Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?
A. Crow (2011)
10.1002/ajh.23132
Sequence of treatments for adults with primary immune thrombocytopenia
J. George (2012)
10.1182/blood-2012-06-438804
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.
T. Robak (2012)
10.1111/j.1600-0609.2011.01718.x
Autoantibody‐mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)
A. Najaoui (2012)
Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
G. Blackhouse (2012)
10.1182/blood-2011-11-393975
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.
Vivek L. Patel (2012)
10.3111/13696998.2012.688902
The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim
R. Deuson (2012)
10.1097/MOH.0b013e328356e909
Thrombopoietin-receptor agonists
P. Basciano (2012)
10.1007/s40258-013-0066-5
Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
D. Lee (2013)
10.1053/j.seminhematol.2013.03.009
Individualized treatment for immune thrombocytopenia: predicting bleeding risk.
C. Neunert (2013)
10.1002/hep.26023
Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance
P. Lapierre (2013)
10.1182/blood-2012-09-455691
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.
S. Gudbrandsdottir (2013)
10.1016/j.clim.2013.04.017
Tolerogenic dendritic cells as a therapy for treating lupus.
C. Llanos (2013)
10.1186/cc12716
Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology?
O. Garraud (2013)
10.2169/INTERNALMEDICINE.52.0080
Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine.
K. Okazuka (2013)
10.1016/B978-0-12-387837-3.00040-7
Immune Thrombocytopenia (ITP)
B. Psaila (2013)
10.1517/14712598.2013.800856
Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia
S. Easdale (2013)
10.2217/imt.13.14
Bortezomib for the treatment of previously untreated multiple myeloma.
A. Romano (2013)
10.1111/jth.12371
Dapsone for primary immune thrombocytopenia in adults and children: an evidence‐based review
C. Rodrigo (2013)
10.1111/bjh.12448
Low‐dose anti‐CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
H. Liebman (2013)
10.1007/s12185-013-1370-4
Pathophysiology and management of primary immune thrombocytopenia
H. Kashiwagi (2013)
10.1161/CIRCRESAHA.113.300512
Platelets as cellular effectors of inflammation in vascular diseases.
M. Rondina (2013)
10.3111/13696998.2012.756400
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada
M. Pettigrew (2013)
10.1093/rheumatology/ket284
Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus.
L. Quartuccio (2014)
10.1016/j.imlet.2013.11.016
Regulatory dendritic cell therapy: from rodents to clinical application.
D. Raïch-Regué (2014)
10.1016/j.autrev.2013.09.008
Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?
Ilse Van Brussel (2014)
10.1016/j.clim.2014.03.016
Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up.
N. Marek-Trzonkowska (2014)
10.1016/j.molimm.2013.10.005
Comparison of the glycosylation of in vitro generated polyclonal human IgG and therapeutic immunoglobulins.
Ilja Ritamo (2014)
10.1002/ajh.23580
Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity
G. Moulis (2014)
10.1182/blood-2014-05-578336
Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France.
G. Moulis (2014)
10.1111/bjh.12888
The temporary use of thrombopoietin‐receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study
M. Mahévas (2014)
10.1002/cpdd.116
PRTX‐100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double‐blind, placebo‐controlled, dose‐escalation study
Edward W. Bernton (2014)
10.1371/journal.pone.0139828
Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G
W. J. R. Fokkink (2015)
10.3109/09537104.2013.870987
Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia
T. González-López (2015)
10.1186/s12913-015-0681-y
Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults
K. Kikuchi (2015)
10.2217/imt.15.1
Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.
D. Pinelli (2015)
10.1016/j.medcli.2013.11.035
[Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
M. F. López (2015)
10.1016/S2352-3026(15)00003-4
Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.
S. Chugh (2015)
10.1016/j.coi.2015.05.005
Engineering antigen-specific immunological tolerance.
Stephan Kontos (2015)
10.1517/17425255.2015.1077808
Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus
N. Jordan (2015)
10.1159/000438960
Clinically and/or Serologically Misleading Findings Surrounding Immune Haemolytic Anaemias
A. Salama (2015)
10.1159/000438731
Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review
A. Salama (2015)
10.1111/bjh.13415
Management of immune thrombocytopenia in adults: a population‐based analysis of the French hospital discharge database from 2009 to 2012
M. Michel (2015)
10.1016/j.coph.2015.05.013
Biotherapies targeting T and B cells: from immune suppression to immune tolerance.
L. Chatenoud (2015)
10.1136/lupus-2015-000104
Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study
M. Urowitz (2015)
10.1111/joim.12395
Human autoimmune diseases: a comprehensive update
Lifeng Wang (2015)
10.4081/hr.2015.5673
Feasibility of Romiplostim Discontinuation in Adult Thrombopoietin-Receptor Agonist Responsive Patients with Primary Immune Thrombocytopenia: An Observational Retrospective Report in Real Life Clinical Practice
M. Carpenedo (2015)
10.1016/J.MEDCLI.2013.11.035
Coste por paciente con respuesta a romiplostim y rituximab en el tratamiento de la trombocitopenia inmune primaria en España
M. López (2015)
10.1016/j.autrev.2014.10.017
Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study.
G. Moulis (2015)
10.1159/000438964
Role of Complement in Autoimmune Hemolytic Anemia
S. Berentsen (2015)
10.1016/S0140-6736(14)61495-1
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
W. Ghanima (2015)
Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells.
Jessica S. Suwandi (2015)
10.1007/s40264-015-0337-1
Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®
Thi-Thanh Loan Nguyen (2015)
Novel insights into anti-CD40/CD154 immunotherapy in transplant
DF Pinelli (2015)
10.1159/000446195
Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand
F. Depré (2016)
10.1016/j.immuni.2016.04.017
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.
Qianxia Zhang (2016)
10.1016/j.pharmthera.2016.03.007
A comprehensive review of the neonatal Fc receptor and its application in drug delivery.
J. P. Martins (2016)
10.4049/jimmunol.1502198
CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor– and Complement Receptor 3–Dependent Mechanisms
A. Amash (2016)
10.1159/000449038
Is Autoimmune Thrombocytopenia Itself the Primary Disease in the Presence of Second Diseases Data from a Long-Term Observation
N. Aboud (2016)
10.1016/j.autrev.2016.06.004
Small molecule phagocytosis inhibitors for immune cytopenias.
A. Neschadim (2016)
10.1111/imr.12419
Autoimmune regulator and self‐tolerance – molecular and clinical aspects
J. Abramson (2016)
10.1016/j.jaut.2016.03.011
Regulatory T cell therapy for type 1 diabetes: May the force be with you.
S. Gitelman (2016)
10.1080/10408363.2016.1200008
Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond
Xiaohong Xu (2016)
10.1182/blood-2015-08-664656
Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.
Xiaojie Yu (2016)
10.1182/blood-2016-03-704734
Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia.
M. Mahévas (2016)
10.1097/MOH.0000000000000270
Controversies in the treatment of immune thrombocytopenia
A. Cuker (2016)
10.1016/j.autrev.2016.03.018
IVIG in autoimmune disease - Potential next generation biologics.
A. Zuercher (2016)
10.1182/blood-2016-03-603365
How I treat refractory immune thrombocytopenia.
A. Cuker (2016)
10.1016/j.addr.2015.10.020
Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity.
L. Northrup (2016)
10.3389/fimmu.2016.00011
Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells
M. König (2016)
10.1111/imr.12403
Development of T‐cell tolerance utilizes both cell‐autonomous and cooperative presentation of self‐antigen
Justin S. A. Perry (2016)
10.1111/vox.12467
New aspects on the efficacy of high‐dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia
B. Mayer (2017)
10.2450/2017.0258-16
Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
F. Depré (2018)
• New aspect in development of immune therapy
• Comprehensive review on the role of platelets in immune system
Efficacy and safety of drugs used in treatment of autoimmune thrombocytopenia
F Depre
• Subcutaneous use of anti-D in ITP



This paper is referenced by
10.21037/aob-20-57
Immune thrombocytopenia: the patient’s perspective
C. Kruse (2021)
10.21037/aob-20-55
FcRn antagonists in ITP
A. Newland (2021)
10.1016/j.lfs.2020.118057
Downregulation of microRNA-155-5p prevents immune thrombocytopenia by promoting macrophage M2 polarization via the SOCS1-dependent PD1/PDL1 pathway.
Yuying Chang (2020)
10.1182/blood.2019003646
Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP.
Ramsha Khan (2020)
10.1007/s10238-020-00630-7
Retrospective analysis of different regimens for Chinese adults with severe newly diagnosed immune thrombocytopenia
Xiaoyue Wang (2020)
10.1080/14397595.2019.1602292
Pharmaceutical immunoglobulins reduce neutrophil extracellular trap formation and ameliorate the development of MPO-ANCA-associated vasculitis
R. Uozumi (2019)
10.1097/BOR.0000000000000599
Treatment of primary and secondary immune thrombocytopenia
R. Kado (2019)
10.2217/imt-2017-0097
Fostamatinib for persistent/chronic adult immune thrombocytopenia.
A. Newland (2018)
10.14740/jh385w
Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia
F. Rodeghiero (2018)
10.1371/journal.pone.0198184
Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice
F. Depré (2018)
10.1111/vox.12549
Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia
B. Mayer (2017)
Semantic Scholar Logo Some data provided by SemanticScholar